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Abstract. The use of 5-aminolevulinic acid to induce 
endogenous porphyrins for the purpose of detection of 
epithelial cancers is being studied extensively in many 
centres around the world. The challenge is to prepare an 
efficacious formulation of 5-ALA for the purpose of cancer 
detection. In this study, we compared two formulations of 
·:topical 5-ALA applications with intravenous administration 
I .. in NPC/CNE-2 xenografts on balb/c nude mice. One of the formulations was a gantrez muco-adhesive patch and the 
1 9ther was a polyvinyl-pyrolidone muco-adhesive patch. The 
t Karl Storz fluorescence endoscopy system was used to obtain 
f macroscopic fluorescence images. Microscopic fluorescence 
: imaging was done by laser confocal microscopy. The 
macroscopic images were further analysed for fluorescence 
intensity distribution. It was found that between the two 
; formulations of topical application of 5-ALA; there was very 
· little difference in the fluorescence biodistribution. When the 
topical applications were compared with the intravenous 
administration, the tumour to normal differential in bio-
distribution was significantly higher with the topical application 
compared to the intravenous application. 
1Introduction 
. The use of endogenous protoporphyrin IX (PpIX) as a 
! 
: photosensitizer to diagnose certain superficial cancers is 
· under extensive study in many centres around the world. 
5-Aminolevulinic acid (5-ALA) is a precursor in the heme 
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DD, nasopharyngeal carcinoma 
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biosynthetic pathway of nucleated cells. It is metabolized 
by certain endogenous enzymes to produce PpIX, which is 
an endogenous photosensitizer. PpIX is an intermediate 
by-product in the heme biosynthetic pathway (1). Survival of 
mammalian cells is crucially dependent upon the biosynthesis 
and metabolism of porphyrins (2). All mammalian nucleated 
cells have the capacity to synthesize heme. PpIX being the 
immediate precursor of heme will also be synthesized in 
equal amounts. However, a tight feedback loop control 
ensures that only a very small amount of PpIX is left at any 
one time (3). Accumulation of the endogenous porphyrins 
only happens under abnormal conditions such as in malignant 
or pre-malignant cell transformation. PpIX preferentially 
accumulates in tumour cells due to changes in the activity of 
two main enzymes, porphobilinogen deaminase (PBG) and 
ferrochelatase (FC) (4-6). In tumour cells, while the activity 
of PBG is increased, the activity of FC is decreased resulting 
in the build up of PpIX. In normal cells, FC catalyses the 
conversion of photosensitive PpIX to heme, which is not 
photosensitive. It chelates the Fe2+ into the porphyrin ring 
structure. The over production of PpIX can also be induced 
by the administration of exogenous 5-ALA or ALA esters 
(topically or intravenously). While 5-ALA is hydrophilic, 
which is a limitation as it restricts its penetration through 
cellular membranes; its ester derivatives have been developed 
to be of increased lipophilicity. 
PpIX is a well-known photosensitizer that yields sufficient 
singlet oxygen when activated by light of appropriate 
wavelength and intensity. 5-ALA is already in use in many 
centres for photodynamic diagnosis (PDD) and photodynamic 
therapy (PDT) in various superficial diseases such as actinic 
keratosis, basal cell carcinoma and squamous cell carcinoma. 
5-ALA induced PpIX is also highly fluorescent. Upon 
activation with blue/violet light, PpIX fluoresces in the red . 
5-ALA is in use for the detection of neoplastic urothelial 
lesions, early stage lung cancer, cervical dysplasia and 
laryngeal neoplasm. 
There have only been a few studies conducted with 
respect to pharmacokinetics of 5-ALA-induced porphyrins 
following topical applications. Most studies have been done 
on applications to the skin. It was observed that the normal 
looking skin overlaying the tumours constitutes a much 
1004 MANIVASAGER et al: MACRO-MICROSCOPIC FLUORESCENCE IMAGING 
lower barrier for 5-ALA penetration than the skin overlaying 
healthy tissues. It was also found that the 5-ALA induces 
more PpIX fluorescence than certain of its esters do. 
Systemic uptake is also reported to be high resulting in high 
accumulation of PpIX in other vital organs such as the liver, 
gut and skin. These studies were compared with intravenous 
or intraperitoneal administrations of 5-ALA (7-10). The aim 
of this study was to compare the uptake and retention 
pharmacokinetics of the topical applications of 5-ALA, in the 
form of muco-adhesive patches and intravenous administration. 
With the use of macroscopic and microscopic fluorescence 
imaging of endogenous PpIX, the optimal selectivity 
between tumour and normal regions was determined. Gantrez 
and polyvfoylpyrolidone were chosen to prepare the patches 
for topical applications, respectively. 
Materials and methods 
Tumour model. CNE-2 is a cell line derived from a poorly 
differentiated nasopharyngeal carcinoma in human. It was a 
gift from Professor K.M. Hui, Cellular and Molecular 
Research, National Cancer Centre, Singapore. The cells 
were grown in culture medium RPMI I640 supplemented 
with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 
IX L-glutamine, 100 units/ml penicillin and streptomycin 
(Gibco) and IX sodium pyruvate in an atmosphere of 5% 
C02 at 37°C. Once confluent they were washed with IX 
phosphate buffered saline and trypsinized with 0.05% 
Trypsin-EDTA (Gibco). The cells were then re-suspended in 
IX Hanks balanced salt solution. Male Balb/c nude mice, 6-8 
weeks old, about 20-25 g were obtained from Animal 
Resource Centre of Australia. The trypsinized cells were 
implanted subcutaneously into the flanks of the nude mice. 
The mice were housed in micro-isolator cages (5 per cage) 
fed with filtered air through air vents. Their food, water and 
bedding were sterilized. The tumour was allowed to grow 
over the next 7-10 days to a size of 5-8 mm in diameter. 
5-ALA muco-adhesive patches. In the Gantrez patch series 
(GP), S-ALA was dissolved in poly (methyl vinyl ether/maleic 
anhydride (Gantrez, ISP, USA)/poly (meth) acrylates (Eudragit, 
Rohm Pharma, Germany)/alcohol solution. In the Polyvinyl 
pyrolidone patch series (PP), 5-ALA was dissolved in 
polyvinyl-pyrolidone (Plasdone, ISP, USA)/alcohol solution. 
A low concentration of I mg/cm2 of 5-ALA and high 
concentration of 2.5 mg/cm2 of 5-ALA were made for both 
formulations of patches. The solution was then poured onto a 
calculated area of polythene sheets and left to dry. The 
patches were cut into I .5 cm2 pieces and sealed in bags and 
stored for further use. Both formulations have muco-adhesive 
properties. 
Animal experiments. Three groups of animals were used. One 
group was used for the intravenous administration of 5-ALA; 
the other two were used for PP and GP applications. For 
topical application, IO mice per group were used. The 
nude mice were anaesthetized with a cocktail of Hypnorm 
(0.3 I5 mg/ml fentanyl citrate and IO mg/ml flaunisone, 
Janssen), Dormicum (5 mg/ml midazolam HCl, David Bull 
Laboratories) and deionised water. The skin overlaying the 
tumour was carefully removed to expose the tumour. 
Extreme care was taken to minimize bleeding as this can 
interfere with the imaging procedure. A white light image of 
the tumour was obtained using the Karl Storz fluorescence 
endoscopy system (FES). This is to help later in identifying 
the tumour and its margins when comparing with the 
fluorescence image. The patches were then applied on the 
tumour making sure that the patch covers the tumour well 
and part of the normal tissue surrounding the tumour. For the 
PP muco-adhesive patches, the patch was applied for 30 min 
and thl;!n removed. The area was rinsed well with 70% 
alcohol to remove any residual 5-ALA. The tumour was 
imaged by the FES, at different time points, post patch 
application, using filtered blue light at 460 nm. For the GP 
muco-aclhesive patches, the patch was left on for I h, before 
it was imaged using the endoscopy system. 
Intravenous administration. 5-ALA was dissolved in 0.9% 
sodium chloride solution and the pH was adjusted to 6.5. The 
mice were administered with a dose of 250 mg/kg-body 
weight by tail vein injections. Ten animals were used for 
each time point. They were then kept in darkness. The mice 
were imaged at I and 3 h, the skin overlaying the tumour was 
removed and the tumours were imaged using the FES. The 
mice were sacrificed, the tumours were removed and snap-
frozen in liquid nitrogen and stored at -80°C for further·· 
analysis. 
Image analysis. The images thus obtained were analyzed 
using the image analysis software, Microimage 4.0. Images 
obtained in blue light needed to be further processed to obtain 
normalized fluorescence intensity images. The processing 
involves contrast enhancement of the original image. This is 
followed by hue extraction where the fluorescence colour ; 
(red) that is needed is extracted. Following hue extraction, 
the thresholding and segmentation of the Area of Interest 
(AOI), which is the tumour in this case, was carried out. This 
gives us the red-black image. From this we obtained the 
relative intensity distribution over the tumour and the normal 
regions. Finally, the normalised intensity image, which is a 
ratio of the tumour fluorescence to the normal (blue) 
background, was obtained. 
Microscopic imaging. Cross sectional cryo-sections of the 
frozen tumours were obtained by using the Microm Cryostat. -
The cryo-sections were sandwich sections, which means the 
thickness of the sections were in the order of 5-10 µrn/I5-
20 µm/5-10 µm. The thinner sections were stained with 
haematoxylin and eosin (H&E). The thicker middle sections 
were imaged using the fluorescence laser confocal 
microscope (Carl Zeiss LSM510, Germany). An argon ion 
laser with a wavelength of 488 nm was used to excite the 
PpIX in the tissue and a 590 nm long pass filter was used to 
detect the PpIX fluorescence. An untreated tumour was used 
as a control and to subtract background fluorescence. 
Statistical analysis. Statistical analysis was done using the 
SPSS 10.0 statistical package for windows. Analysis was 
done by comparing means (ANOV A). The mean difference 
was found to be statistically significant (p<0.05). 
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Figure 1. (A), White light image obtained by endoscopy system; (B), Red-black image obtained during image processing indicating fluorescent area of 
interest; (C), Fluorescence intensity distribution indicating low (green), medium (yellow) and high (red) regions within the tumour; (D), Enhanced 
fluorescence image of tumour. 
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Figure 2. Normalised fluorescence intensity of tumour versus normal as a 
function of time for intravenous administration. 
Results 
The normalized intensity for the macroscopic fluorescence 
images was obtained by using the Microlmage 4.0. software. 
From the series of processed images obtained (GP patch) at 
1-3 h post application (Fig. 1) it can be seen clearly that 
PpIX is qighly selective to tumourous regions. When the 
normalized fluorescence intensities that were obtained 
from the tumours were plotted in histograms, both the PP 
and the GP patches were found to have tumour fluorescence 
increasing with time. The tumour to normal fluorescence 
ratio (TIN) also increased correspondingly. For the PP 
patches (1 mglcm2 and 2.5 mglcm2), by 3 h the TIN ratio 
Was almost 2.6 (p<0.05). At 6-h post 5-ALA patch 
application, the TIN ratio was 2 (p<0.05). The GP patches 
(1 mglcm2 and 2.5 mglcm2), followed similar patterns as 
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Figure 3. (A), Normalised fluorescence intensity of tumour versus normal as a 
function of time for 1 mglcm2 PP patch; (B), Normalised fluorescence intensity 
of tumour versus normal as a function of time for 2.5 mglcm2 PP application. 
the PP patches (Figs. 3 and 4). By 3 h TIN ratio was also high, 
almost 2. When 5-ALA was intravenously administered, the 
background normal tissue fluorescence was high between 
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Figure 4. (A), Normalised fluorescence intensity of tumour versus normal, 
as a function of time for 1 mg/cm2 GP application; (B), Normalised 
fluorescence intensity of tumour versus normal as a function of time for 
2.5 mg/cm2 GP application. 
1-3 h (Fig. 2). Hence the tumour to normal (T/N) ratio was 
not found to be statistically significant. However, although 
the overall fluorescence intensity for both tumour and normal 
tissue was high for the earlier time points there was still 
discrimination of the tumour. Cutaneous fluorescence in 
remote distal regions was also found to be high indicating 
that the S-ALA that is still circulating is continuing to induce 
localised PpIX production in different parts of the anatomy. 
Microscopic confocal images were obtained using the laser 
scanning confocal microscope (LSMS 10). Only tumours with 
and without the S-ALA treatment were compared, as this is a 
xenograft. Fig. SA shows the PpIX micro-fluorescence in a 
NPC/CNE-2 tumour. Fig. SB is the H&E counter-staining of 
the same section. It was found that the S-ALA is well taken up 
by the NPC/CNE-2 tumour. 
Discussion 
Human tumour xenografts on Balb/c nude mice were used as 
a model to investigate the efficacy of the topical application 
in terms of PpIX production of tumour cells in an in vivo 
system. Intravenous administration of S-ALA for endogenous 
porphyrin based PDD and PDT, has been the normal mode 
of administration. The main drawback of intravenous 
administration is that the circulating S-ALA causes extensive 
cutaneous PpIX accumulation, and makes it necessary for the 
patients to avoid light, as they would still be photosensitive. 
Thus, there are merits for local S-ALA delivery via topical 
applications. This delivery system can take many forms such 
as rinses, gels or creams, which have to be constituted 
A 
B 
Figure 5. (A), PpIX microscopic fluorescence of NPC/CNE-2 xenograft 
(x20). (B), Haematoxylin and eosin staining of NPC/CNE-2 xenograft 
(x20). 
extemporaneously when, needed due to instability of S-ALA. 
Patches prepared for this study can be made and stored in an 
airtight container at room temperature for three to six months. 
These patches also have muco-adhesive properties and can 
be good candidates for use in the oral cavity PDD and PDT. 
Oral rinses require the patient to continuously rinse for 20 min. 
Hence oral rinses are not practical for routine clinical use. 
Also the contact time for S-ALA on oral tissue is short with 
the use of an oral rinse. 
In our investigations, it was detected that the intravenous 
S-ALA administration not only gives high fluorescence of 
tumour but also that of normal tissues at the early time points 
both 1 and 3 h post S-ALA administration. This is due to 
considerable amounts of circulating S-ALA inducing local 
PpIX (and not circulating PpIX). In most cases normal liver 
and skin appeared to have high production levels of PpIX. 
The TIN fluorescence ratio was found to be not significant 
between 1.S-2 h. The fluorescence intensity pattern observed 
when both the GP and PP patches applied were found to 
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be superior to the intravenous administration. The T/N 
fluorescence ratio is significantly high at 3 h following 
topical PP or GP muco-adhesive patch application. Despite 
the expected differences in the availability of 5-ALA in the 
GP and PP patches, their in vivo performances did not show 
significant differences. This indicates that the rate-limiting 
step to 5-ALA delivery to the tumour tissue was the trans-
dermal transport of the hydrophilic 5-ALA compound. In 
conclusion, there was no difference between the two polymer 
based patches. Apart from the difference in the intensity of 
the fluorescence amongst the different concentrations, the 
TIN fluorescence ratio was consistent in both the low and 
high 5-ALA concentration patches at both 3 and 6 h. 
Between the intravenous administration and the topical 
application, the difference lies in the fact that there is low 
systemic uptake in the topical application and therefore TIN 
fluorescence ratio is larger and found to be statistically 
significant with the topical patches. 
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